KindlyMD (NASDAQ:NAKA) CEO Purchases 32,134 Shares of Stock

KindlyMD, Inc. (NASDAQ:NAKA) CEO David Bailey acquired 32,134 shares of the stock in a transaction that occurred on Wednesday, August 19th. The stock was acquired at an average price of $5.59 per share, with a total value of $179,629.06. Following the completion of the transaction, the chief executive officer directly owned 32,134 shares of the company’s stock, valued at $179,629.06. This trade represents a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this link.

KindlyMD Stock Performance

Shares of NAKA traded up $0.76 during midday trading on Friday, hitting $7.06. 451,586 shares of the stock were exchanged, compared to its average volume of 199,173. The firm has a market cap of $126.37 million, a P/E ratio of -0.20 and a beta of 15.95. KindlyMD, Inc. has a 52-week low of $3.33 and a 52-week high of $422.40. The stock has a fifty day simple moving average of $4.48 and a 200 day simple moving average of $7.24.

KindlyMD (NASDAQ:NAKA) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($6.65) EPS for the quarter. KindlyMD had a negative net margin of 1,067.93% and a negative return on equity of 63.45%. The business had revenue of $35.87 million during the quarter. As a group, equities research analysts forecast that KindlyMD, Inc. will post -11.31 EPS for the current fiscal year.

Institutional Investors Weigh In On KindlyMD

Several hedge funds and other institutional investors have recently bought and sold shares of NAKA. Virtu Financial LLC purchased a new stake in shares of KindlyMD in the fourth quarter valued at about $151,000. Invesco Ltd. purchased a new position in shares of KindlyMD during the fourth quarter worth about $211,000. NewEdge Advisors LLC purchased a new position in shares of KindlyMD during the fourth quarter worth about $316,000. Charles Schwab Investment Management Inc. purchased a new stake in KindlyMD during the 4th quarter valued at approximately $727,000. Finally, State Street Corp acquired a new stake in KindlyMD during the 4th quarter worth approximately $593,000.

Analysts Set New Price Targets

A number of equities analysts recently commented on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of KindlyMD in a research note on Friday, August 7th. TD Cowen upped their price objective on KindlyMD from $1.00 to $17.00 and gave the stock a “buy” rating in a research report on Monday, July 27th. Finally, Wall Street Zen upgraded KindlyMD to a “sell” rating in a report on Saturday, May 23rd. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $22.33.

More KindlyMD News

Here are the key news stories impacting KindlyMD this week:

• Positive Sentiment: CEO David F. Bailey purchased 4,918 shares at an average price of $5.12, investing approximately $25,180. The transaction raised his direct ownership to 3.18 million shares, which may reassure investors about management’s confidence in KindlyMD’s long-term outlook. CEO stock purchase article
• Neutral Sentiment: Maxim Group improved its EPS forecasts for the fourth quarter of 2026 and the first two quarters of 2027, projecting smaller losses of $0.48, $0.76 and $0.74 per share, respectively. These revisions are modestly encouraging but still indicate that KindlyMD is not expected to reach profitability in the near term. KindlyMD analyst estimates
• Negative Sentiment: Maxim lowered its third-quarter 2026 EPS forecast to a $0.49 loss from a $0.43 loss, cut its fourth-quarter 2027 estimate to a $0.43 loss from a $0.41 loss, and reduced its full-year 2027 forecast to a $2.12 loss from a $1.44 loss. The full-year downgrade points to weaker expected profitability and offsets some of the improved quarterly estimates.
• Negative Sentiment: KindlyMD’s latest reported quarter showed a $6.65-per-share loss on $35.87 million of revenue, alongside a deeply negative net margin. The company is expected to post a loss of approximately $11.31 per share for the current year, while analyst coverage remains mixed, including sell ratings. KindlyMD financial and insider trading data

About KindlyMD

Kindly MD, Inc (“KindlyMD” or “Kindly”) is a Utah company formed in 2019. KindlyMD is a healthcare data company, focused on holistic pain management and reducing the impact of the opioid epidemic. KindlyMD offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Kindly believes these methods will help prevent and reduce addiction and dependency on opiates. Our specialty outpatient clinical services are offered on a fee-for-service basis.